AI News NQ Analysis

Survey on Awareness of Implantable Contact Lenses (Phakic Posterior Chamber Lenses) Among Men and Women in Their 20s-40s with Vision of 0.1 or Less

NQ Score 50/100

AI Summary (NQ-processed)

At Working Co., Ltd., the Japanese distributor of "IPCL®," an implantable contact lens approved by the Ministry of Health, Labour and Welfare in April 2025, conducted a survey on implantable contact lenses among men and women in their 20s to 40s nationwide. The survey found that over 70% of respondents were aware of the treatment, with nearly the same percentage expressing interest. The primary drivers of interest were the inconvenience and ongoing cost of glasses and traditional contact lenses, while the main deterrents were fear of surgery and safety concerns. Interest was notably higher among women in their 20s and 30s.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is IPCL and how does it correct vision problems?
A: IPCL is an implantable contact lens treatment method that corrects myopia and astigmatism by inserting a small lens into the eye.
Q: When did IPCL receive regulatory approval in Japan?
A: IPCL obtained regulatory approval from the Ministry of Health, Labour and Welfare in April 2025 and was launched in September 2025.
Q: What makes IPCL a highly reversible treatment compared to LASIK?
A: Unlike LASIK, IPCL does not involve shaving the cornea, which means the inserted lens can be removed from the eye in the future.
Q: What specific materials are used to make the IPCL lens?
A: The IPCL lens uses an acrylic polymer material primarily composed of HEMA, which is also used in cataract lenses and contact lenses.
Q: What percentage of the survey respondents were interested in implantable contact lenses?
A: The survey results showed that about 70 percent, specifically 71.9 percent, of the subjects were interested in this treatment method.